Skip to main content
. 2021 Jul 28;5(10):bvab130. doi: 10.1210/jendso/bvab130

Table 1.

Clinical, laboratory and imaging features of the entire cohort of SAT patients (n = 198) evaluated in the years 2016-2020

Study population (N = 198) Results
Sex
- Female (%) 167 (84)
- Male (%) 31 (16)
Mean age (SD) 44.6 (±12)
Patients with respiratory symptoms prior to SAT onset (%) 56 (28)
Median time from respiratory symptoms to SAT (IQR) 30 (28-45)
Patients with bilateral neck pain (%) 48 (24)
Patients with fever (%) 145 (73)
Laboratory and imaging findings
FT4 (IQR) 24.3 (4.6)
FT3 (IQR) 5.8 (1.7)
FT4/FT3 (IQR) 4.3 (1.2)
TSH (IQR) 0.1 (0.2)
ESR (IQR) 43 (45)
CRP (IQR) 3.8 (2.2)
Tga (IQR) 69 (70)
Patients with positive TgAbs (%) 62 (31)
- Median titer (IQR) 65 (52)
Patients with positive TPOAbs (%) 27 (14)
- Median titer (IQR) 35 (65)
Thyroid volume (IQR) 22.3 (6)
Scintigraphy
- Absent/reduced uptake 54
- Normal uptake 0
- Not available 144
Treatment and follow-up
Type of treatment (%)
- Steroids 175 (89)
- NSAIDs 15 (7)
- None 8 (4)
Median duration of steroid treatment (days) (IQR) 90 (40)
Hypothyroidism at 3 monthsb (%) 57 (29)
SARS-CoV-2 status (year 2020)
- pos-SARS-CoV-2 (%) 18 (39)
- neg-SARS-CoV-2 (%) 28 (61)

Normal ranges: FT4 6-16 nmol/L; FT3 2.3-4.2 pmol/L; TSH 0.4-4.5 mIU/L; ESR < 15 mm/h; CRP < 1.5 mg/L; Tg < 35 µg/L; TgAbs < 30 IU/mL (positive cutoff); TPOAbs < 10 IU/mL (positive cutoff).

Abbreviations: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; FT3, free triiodothyronine; FT4, free thyroxine; IQR, interquartile range; NSAIDs, nonsteroidal anti-inflammatory drugs; SARS-CoV-2: severe acute respiratory syndrome virus 2; SAT, subacute thyroiditis; Tg, thyroglobulin; TgAbs, thyroglobulin antibodies; TPOAbs, thyroid peroxidase antibodies.

aMeasured in patients with TgAbs < 9.3 IU/mL (interfering cutoff).

bEvaluated in 182 subjects with a minimum follow-up of 3 months.